BioStem Technologies, Inc.
BSEM
$14.50
-$0.03-0.21%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 210.39M | 131.34M | 57.91M | 16.59M | 5.94M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 210.39M | 131.34M | 57.91M | 16.59M | 5.94M |
| Cost of Revenue | 10.86M | 6.94M | 3.40M | 1.28M | 757.30K |
| Gross Profit | 199.54M | 124.39M | 54.51M | 15.31M | 5.18M |
| SG&A Expenses | 177.73M | 112.94M | 54.61M | 23.54M | 15.07M |
| Depreciation & Amortization | 219.20K | 218.40K | 224.30K | 228.90K | 232.10K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 189.78M | 120.63M | 58.74M | 25.49M | 16.38M |
| Operating Income | 20.61M | 10.70M | -829.00K | -8.90M | -10.44M |
| Income Before Tax | 19.53M | 8.84M | -2.69M | -10.71M | -11.74M |
| Income Tax Expenses | 5.83M | 3.50M | 1.18M | -- | -- |
| Earnings from Continuing Operations | 13.70 | 5.34 | -3.88 | -10.71 | -11.74 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | 48.70K |
| Net Income | 13.70M | 5.34M | -3.88M | -10.71M | -11.70M |
| EBIT | 20.61M | 10.70M | -829.00K | -8.90M | -10.44M |
| EBITDA | 20.83M | 10.91M | -610.40K | -8.68M | -10.21M |
| EPS Basic | 0.83 | 0.30 | -0.31 | -0.79 | -0.89 |
| Normalized Basic EPS | 0.77 | 0.38 | -0.09 | -0.43 | -0.52 |
| EPS Diluted | 0.58 | 0.14 | -0.38 | -0.80 | -0.90 |
| Normalized Diluted EPS | 0.56 | 0.25 | -0.14 | -0.43 | -0.52 |
| Average Basic Shares Outstanding | 64.14M | 61.31M | 58.27M | 54.52M | 52.75M |
| Average Diluted Shares Outstanding | 81.10M | 73.46M | 65.37M | 54.52M | 52.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |